Covered transjugular intrahepatic portosystemic stent-shunt vs large volume paracentesis in patients with cirrhosis: A real-world propensity score-matched study

Table 1 Baseline characteristics in each cohort

		Whole cohort			Propensity score - matched cohort
		TIPSS (n = 75)	LVP (n = 75)	P value	TIPSS (n = 40)	LVP (n = 40)	P value
Age (mean yr)		59.1 ± 9.4	61.8 ± 11.5	0.119	61.2 ± 9.1	61.5 ± 12.2	0.885
Gender	Male	41	46	0.275	23	26	0.616
	Female	34	29	0.275	17	14	0.491
Aetiology	ArLD	60	47	0.174	32	22	0.297
	AIH	1	1		0	1
	NAFLD	9	9		3	8
	Cryptogenic	2	5		2	4
	HCV	1	7		3	2
	HBV	0	2		0	1
	PBC	0	3		0	1
	PSC	0	1		0	1
	Other	2	0		2	1
	History of HCC	7	5	0.220	3	2	0.644
History of spontaneous bacterial peritonitis		17	15	0.849	13	6	0.079
Type of ascites (recurrent/refractory)		61/14	35/40	< 0.001	22/18	31/9	0.03
Liver transplantation		7	22	< 0.001	4	12	0.029
Varices at baseline		21	26	0.304	12	13	0.135
Use of non-selective beta-blockers		16	20	0.484	10	13	0.459
Mean follow up (mo)		27.5 ± 29.3	16.4 ± 16.4	0.005	26.3 ± 35.3	15.5 ± 14.9	0.08
Median follow up (range, mo)		16.5 (0.47-179.53)	10.3 (1.4-73.86)	0.050	8.2 (0.47-179.53)	10.3 (1.5-73.86)	0.823

TIPSS: Transjugular intrahepatic portosystemic stent shunt; LVP: Large volume paracentesis; ArLD: Alcohol related liver disease; AIH: Autoimmune hepatitis; NAFLD: Non alcoholic fatty liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; HCC: Hepatocellular carcinoma.